The global antibody-drug conjugates market size is forecasted to grow USD 44.45 Billion by 2026 from USD 14.72 Billion in 2021, growing at a CAGR of 24.74% between 2021 to 2026.
Antibody-drug conjugates are very effective biopharmaceutical drugs that are used to treat certain diseases. Antibody-drug conjugates are a type of cancer treatment that is safer and more effective than many other cancer treatments. Antibody-drug conjugates, unlike chemotherapy, are designed to target and destroy just cancer cells. Antibody-drug conjugates are a type of chemical molecule that combines antibodies with a cytotoxic medication that is physiologically active. Antibody-drug conjugates are composed of three components: a particular antibody for binding, a cytotoxic agent to kill cancer cells, and a chemical linker to connect the cytotoxic agent to the antibody. These drug conjugates are thought to be the medicinal agents of the future. The potency of a cytotoxic agent embedded in an antibody-drug conjugate is 100–1000 times more than the potency of the cytotoxic agent acting alone. Formulating an antibody-drug conjugate cancer has been difficult for a long time.
Nonetheless, the pharmaceutical industry's modernization aided the market in overcoming hurdles such as identifying a target, generating a high-affinity antibody, internalization capabilities, linker creation, and drug stability and optimization. According to the National Cancer Institute, "by 2024, the number of people living beyond the cancer diagnosis is predicted to reach over 19 million." During the research period, the ADC market is likely to be driven by increased demand for cost-effective and high-quality cancer therapy.
MARKET DRIVERS:
The global antibody-drug conjugates market growth is majorly driven by the factors such as an increase in the prevalence of cancer and a growing geriatric population across the globe.
The market growth is further propelled by ongoing technological advancements in the healthcare sector. The World Health Organization (WHO) predicts that by 2050, the number of persons aged 65 and more would have increased to 16% of the overall population, up from 7% in 2000. In developing nations, aging has become a significant risk factor for various illnesses, including cancer and others. As a result, the market's growth is likely to be fuelled by the expanding elderly population throughout the forecast period. Also, significant innovative progressions are assisting the market growth. However, the growing use of Antibody Drug Conjugates in various segments of end-users across emerging nations is a factor driving market expansion.
Furthermore, preclinical research, increased antibody therapy research, increased research on advanced drug discoveries, and increased research on cancer disorders all impact market growth. A biomacromolecule was created by combining monoclonal antibodies with chemical payloads, and it is today one of the most potent weapons in the complete immunotherapy arsenal. Moreover, rising chronic diseases such as cancer and the growing obese population are most likely to augment the market growth. In addition, increasing collaboration between research institutions, biopharmaceutical firms, and biotechnology firms fuel the market. They are likely to increase the market of antibody-drug conjugates throughout the forecast period. The market for cancer antibody-drug conjugates and the boom that has resulted from a high number of new medications in the clinical pipeline has been effective in attracting global attention. Increasing investments by pharmaceutical and biotechnology companies are encouraging market growth. The market's major players are concentrating on various growth tactics, such as acquiring regulatory clearance for new products to increase their product range. For example, the U.S. Food and Drug Administration (FDA) approved Policy, an antibody-drug conjugate, by Roche Holding AG, a Swiss healthcare business, in June 2019.
MARKET RESTRAINTS:
Stringent government regulations and reimbursement policies are impeding market growth. High costs associated with the procedures and the lack of funds are further expected to hamper the growth rate of the global antibody drug conjugates market.
COVID-19 impact on the global antibody drug conjugates market:
The Global pandemic COVID-19 is a highly contagious disease spread across 210 countries and had affected more than 2 million and led to many people dying. As a result of the steps taken by various governments to limit transmission, a massive economic catastrophe ensued. The outbreak of COVID-19 has impacted the market, resulting in a market decline in the first half of 2020. The reduction is mostly due to the COVID-19 outbreak, which has resulted in tight containment measures such as social separation, remote working, and the shutdown of companies and other businesses. The entire supply chain has been interrupted, which has had a detrimental impact on the antibody drug conjugates market.
REPORT COVERAGE:
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2021 to 2026 |
|
Base Year |
2020 |
|
Forecast Period |
2021 to 2026 |
|
Segments Covered |
By Pipeline, Technology, End-User, and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regions Covered |
North America, Europe, APAC, Latin America, Middle East & Africa |
|
Market Leaders Profiled |
Seattle Genetics, Genentech, Takeda Pharmaceuticals, F. Hoffmann-La Roche, Bayer Healthcare, Agensys, Inc., Immunogen, Novartis, Oxford Biotherapeutics, and Synthon Biopharmaceuticals. |
This market research report on the global antibody drug conjugates market has been segmented and sub-segmented into the following categories and analyzed market size and forecast until 2026.
Antibody Drug Conjugates Market - By Pipeline:
Antibody Drug Conjugates Market - By Technology:
Antibody Drug Conjugates Market - By End User:
Antibody Drug Conjugates Market - By Region:
Geographically, the North American market is expected to lead the global antibody drug conjugates market during the forecast period. The North American antibody drug conjugates market was worth 3.6 billion in 2020. The rise in awareness among patients of early diagnosis is driving the North American market. The increase in usage of antibody-drug conjugates (ADC) and the rise in the prevalence of cancer are further accelerating the North American market. The United States is forecasted to dominate the North American Antibody Drug Conjugates Market during the forecast period due to the presence of high cancer patients, increased investments by the market participants in the pipeline analysis, and technological advancements. The Canadian market is expected to grow at a significant CAGR due to increased government funding in the research and large pharmaceutical companies.
The European antibody-drug conjugate market is predicted to be the second-largest regional market globally and estimated to value USD 7.56 billion in 2025. Y-O-Y growth in the number of cancer & bone marrow surgeries happening in Europe, rise in awareness programs by the government, and the presence of significant market players are majorly promoting the European market. In Europe, the German market is predicted to dominate, followed by France and U.K. The presence of favorable reimbursement policies and the rise in government and private to develop advanced technology in these regions propels the European antibody-drug conjugate market.
The Asia-Pacific region is the fastest-growing region in the global market due to the rise in prevalence of cancer, and expanding health care infrastructure is driving the market. The rising awareness among consumers and growing government initiatives are propelling the Asia Pacific Antibody Drug Conjugates Market.
Latin America, and Middle East & Africa are expected to have lucrative growth opportunities in the coming years.
KEY MARKET PARTICIPANTS:
Some of the promising companies operating in the global antibody drug conjugate market profiled in the report are Seattle Genetics, Genentech, Takeda Pharmaceuticals, Hoffmann-La Roche, Bayer Healthcare, Agensys, Inc., Immunogen, Novartis, Oxford Biotherapeutics, Synthon Biopharmaceuticals.
KEY MARKET DEVELOPMENTS:
Appendix
Related Reports
